28
Oct
2016

Amgen Increases Prices (Again), Humana Flexes Muscle, and MIT Starts a $150M Engine

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100